Interim Management Statement

WORLDWIDE HEALTHCARE TRUST PLC                         

    Interim Management Statement - 3 months to 31 December 2010 (unaudited)    

Worldwide Healthcare Trust PLC invests worldwide in pharmaceutical, 
biotechnology and related companies in the healthcare sector with the objective
of achieving a high level of capital growth.

During the 3 month period ended 31 December 2010 the Company's undiluted net
asset value per share total return was +2.3% and the share price total return
was +1.7%, compared to a rise of 4.4% in the Company's benchmark, the MSCI
World Health Care Index measured in sterling terms on a total return basis. The
underperformance was due, in part, to mixed returns from some of the
portfolio's large Biotechnology holdings, Japanese generic companies and also
medical device stocks. During the three-month period a total of 358,607 shares
were repurchased to be held in treasury at an average discount of 8.6%. Since
the period end, to 9 February 2011, no further shares have been bought back by
the Company. As at the date of this report there are 43,141,611 shares in
issue.

In the period from 31 December 2010 to 9 February 2011, the Company's fully
diluted net asset value per share total return was -1.6% and the share price
total return was -1.0% compared to a fall of 0.8% in the Company's benchmark,
all measured on a total return basis.

During the three month period and up to 9 February 2011, a total of 114,302 new
shares were issued, raising £730,000 of additional funds for the Company, as a
result of holders of subscription shares exercising their subscription rights.
The next subscription date is 3 May 2011 and the subscription price is 638p per
share. As at the date of this report there are 8,191,112 subscription shares in
issue.

Trust Characteristics

                            31 December 2010         30 September 2010         
                                                                               
Number of holdings          59                       57                        
                                                                               
Net assets (£m)             334.9                    328.4                     
                                                                               
Yield                       1.2%                     1.2%                      
                                                                               
Gearing (AIC basis)         115                      112                       
                                                                               
Share price (p)             702.00                   690.00                    
                                                                               
NAV (p) -undiluted          777.67                   756.86                    
                                                                               
NAV (p) diluted: sub shares 755.16                   737.76                    
                                                                               
NAV (p) - fully diluted for 754.79                   737.76*                   
                                                                               
sub shares and treasury                                                        
shares                                                                         
                                                                               
(Discount)/premium          (9.7%)                   (8.8%)                    
(undiluted)                                                                    
                                                                               
(Discount/premium(diluted - (7.0%)                   (6.5%)                    
sub shares)                                                                    
                                                                               
(Discount)/premium (fully   (7.0%)                   (6.5%)*                   
diluted)                                                                       
                                                                               
Subscription share price    83.50                    81.00                     
(p)                                                                            

Source: Frostrow Capital LLP

*There were no shares held in treasury as at 30 September 2010.

10 Largest Investments

Name                                 % of                       % of           
                                                                               
                                   portfolio                 portfolio         
                                                                               
                              at 31 December 2010       at 30 September 2010   
                                                                               
Merck                                 6.0                       5.9            
                                                                               
Roche                                 6.0                       5.4            
                                                                               
Pfizer                                5.4                       6.9            
                                                                               
Novartis                              5.0                       8.0            
                                                                               
Johnson & Johnson                     4.3                       6.1            
                                                                               
Genzyme                               3.5                       2.0            
                                                                               
Bristol-Myers Squibb                  3.5                       4.4            
                                                                               
Mitsubishi Tanabe                     3.4                       2.6            
                                                                               
Amgen                                 2.5                       2.4            
                                                                               
GlaxoSmithKline                       2.2                       2.2            
                                                                               
                                     41.8                       45.9           

Source: Frostrow Capital LLP

Sector Analysis

                                     % of                       % of           
                                                                               
                                   portfolio                 portfolio         
                                                                               
                              at 31 December 2010       at 30 September 2010   
                                                                               
Large capitalisation                 65.7                       63.9           
                                                                               
Small capitalisation                 34.3                       36.1           
                                                                               
Total                                100.0                     100.0           

Source: Frostrow Capital LLP

Geographical Analysis

                                     % of                       % of           
                                                                               
                                  portfolio                  portfolio         
                                                                               
                             at 31 December 2010        at 30 September 2010   
                                                                               
North America                        64.9                       64.1           
                                                                               
Europe                               21.1                       24.3           
                                                                               
Far East                             13.2                       11.6           
                                                                               
Israel                               0.8                         -             
                                                                               
Total                               100.0                      100.0           

Source: Frostrow Capital LLP

Total Return Performance to 31 December 2010

                3 Months        1 Year          3 Years         5 Years        
                                                                               
Share price     +1.7%           +15.5%          +45.8%          +29.1%         
                                                                               
NAV Fully       +2.3%           +17.7%          +47.0%          +40.8%         
diluted                                                                        
                                                                               
Benchmark*      +4.4%           +8.8%           +35.4%          +34.5%         

Source: NAV (total return; fully diluted) and Share Price (total return)
Morningstar. Benchmark - Thomson Reuters

* Benchmark - Blended Datastream World Pharmaceutical and Biotechnology Index/
MSCI World Health Care Index, both measured in sterling terms on a total return
basis. With effect from 1 October 2010, the performance of the Company is
measured against the MSCI World Health Care Index measured on a total return
basis in sterling terms. Prior to this date, performance was measured against
the Datastream World Pharmaceutical and Biotechnology Index on a total return
basis in sterling terms.

Past performance is not a guide to future performance.

This Interim Management Statement has been prepared solely to provide
information to meet the requirements of the UK Listing Authority's Disclosure
and Transparency Rules.

This Interim Management Statement is available on the Company's website 
www.worldwidewh.com.

The Company's net asset value per share is announced daily and is available,
together with the share price, on the TrustNet website at www.trustnet.com

SEDOL Codes:

Shares - 0338530

Subscription Shares - B3VMCB0

ISIN -

Shares - GB0003385308

Subscription Shares - GB00B3VMCB07

For further information contact: Mark Pope on 0203 008 4913

Frostrow Capital LLP

Company Secretary

16 February 2011